Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Toyota Global Sales Fall as China Demand Slumps 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Add as a preferred source on Google
NEW YORK, April 03, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission on April 03, 2018. The annual report can be accessed on the Company’s investor relations website at http://ir.beyondspringpharma.com.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
Contact:
Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
[email protected] / [email protected]
Investor Relations:
Laura Perry / Joseph Rayne
Argot Partners
212.600.1902
[email protected]
